Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. NEXAVAR (sorafénib)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

NEXAVAR (sorafénib)

Medicine - Posted on Mar 04 2020
Active substance (DCI)
  • sorafénib
history (5)
  • 10/23/19

    NEXAVAR (sorafénib)

    Réévaluation L’essentiel Avis défavorable au maintien du remboursement dans le traitement du carcinome rénal avancé après éc...
    icône flèche
  • 10/23/19

    NEXAVAR (sorafénib)

    Maintien du remboursement L’essentiel Avis favorable au maintien du remboursement uniquement dans le carcinome hépatocellula...
    icône flèche
  • 6/3/15

    NEXAVAR (sorafenib), protein kinase inhibitor

    Minor improvement in the treatment of locally advanced, inoperable or metastatic, differentiated thyroid carcinoma refractor...
    CAV :
    54321
    icône flèche
  • 3/5/08

    NEXAVAR

    NEXAVAR
    CAV :
    54321
    icône flèche
  • 9/6/06

    NEXAVAR

    NEXAVAR
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XE05
Manufacturer
BAYER HEALTHCARE SAS
Presentation

NEXAVAR 200 mg, comprimé pelliculé (code CIS : 64463662)
4 plaquette(s) polypropylène aluminium de 28 comprimé(s) - CIP : 34009 376 137 2 9

All our publications
    Digestive system cancers Drug therapy Endocrine gland cancers Urologic cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
7CafkyHSj81RqgtL